Affordable Access

deepdyve-link
Publisher Website

The antagonic behavior of GPIHBP1 between EAT and circulation does not reflect lipolytic enzymes levels in the tissue and serum from coronary patients.

Authors
  • Barchuk, Magalí1
  • Nagasawa, Takumi2
  • Murakami, Masami2
  • López, Graciela1
  • Baldi, Julio3
  • Miksztowicz, Verónica4
  • Rubio, Miguel3
  • Schreier, Laura1
  • Nakajima, Katsuyuki2
  • Berg, Gabriela5
  • 1 Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina. , (Argentina)
  • 2 Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. , (Japan)
  • 3 Universidad de Buenos Aires, Hospital de Clínicas "José de San Martín", División de Cirugía Cardíaca, Buenos Aires, Argentina. , (Argentina)
  • 4 Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina; Universidad de Buenos Aires, CONICET, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina. , (Argentina)
  • 5 Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina; Universidad de Buenos Aires, CONICET, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina. Electronic address: [email protected] , (Argentina)
Type
Published Article
Journal
Clinica chimica acta; international journal of clinical chemistry
Publication Date
Aug 07, 2020
Volume
510
Pages
423–429
Identifiers
DOI: 10.1016/j.cca.2020.08.001
PMID: 32771483
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. Recently, triglyceride rich lipoproteins are proposed to contribute to CAD risk; its concentrations would be partly determined by lipoprotein lipase (LPL) and endothelial lipase (EL). Epicardial adipose tissue (EAT), a visceral AT surrounding myocardium and coronary arteries, emerged as an important actor in CAD; the increase in its volume could be a consequence of LPL and EL. Circulating enzymes levels would be conditioned by local tissue factors. Our aim was to evaluate LPL, EL and their regulators levels in serum and EAT from CAD patients, searching for possible parallelisms and their role in the lipoprotein profile. In serum, EAT and subcutaneous AT (SAT) from patients undergoing coronary artery bypass graft (CABG, n = 25) or valve replacement (No CABG, n = 25), LPL, EL and glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein-1 (GPIHBP1) expression were evaluated. Besides, Apoprotein (Apo)CII, CIII and AV were determined in serum, along with lipoprotein profile. Insulin-resistance markers were higher in CABG (p < 0.05). Serum LPL levels were decreased (p = 0.045), while EL levels increased (p < 0.001) in CABG, without differences in EAT or SAT. Circulating GPIHBP1 concentrations were decreased in CABG (p = 0.047), while EAT GPIHBP1 expression was increased (p < 0.001). ApoCII and ApoAV concentrations were higher in CABG (p = 0.016 and p = 0.047, respectively), without differences in ApoCIII concentrations between groups. In EAT, LPL and EL protein levels were not changed in CAD, although GPIHBP1 protein levels were higher. EAT would be a minor contributor to the circulating levels of the enzymes. Copyright © 2020 Elsevier B.V. All rights reserved.

Report this publication

Statistics

Seen <100 times